other material
confidence high
sentiment positive
materiality 0.75
Pliant Therapeutics reports positive Phase 2a data for bexotegrast in IPF; FVC decline reduced 68% vs placebo
PLIANT THERAPEUTICS, INC.
- Bexotegrast 320 mg well tolerated up to 40 weeks; no drug-related serious adverse events.
- FVC decline reduced 68% vs placebo: mean FVCpp change -0.8% vs -2.5% at Week 24.
- 89% of patients with FVC increase at Week 12 maintained increase through Week 24.
- QLF imaging showed fibrosis stabilization in bexotegrast group vs progression in placebo.
- BEACON-IPF Phase 2b trial (160/320 mg, ~270 patients) to initiate in mid-2023.